Should the costs of development inhibit research into new antihypertensive drugs?
Although hypertensive therapy has had spectacular successes, there is now an important trend away from mere control of blood pressure to the attempt to normalize the cardiac and vascular accompaniments of the disease, such as left ventricular hypertrophy and medial hypertrophy of resistance arterioles. New agents may need to be developed to cope with these specific aims. The costs of development should not inhibit these important goals.